Company Reports Q1 Revenue of $120.9M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy NOTV?
Reports Q1 revenue $120.9M vs. $119.9M last year. Robert Leasure Jr., President and Chief Executive Officer, commented, "During the first quarter of fiscal 2026, we continued to execute on our operational and financial priorities, with a sustained focus on client service and margin discipline. Revenue increased slightly compared to the first quarter of fiscal 2025, and demand trends, particularly within our DSA segment, remained encouraging and reflect the value clients place on our capabilities and partnership approach. Client satisfaction and reliable, on-time delivery of high-quality products and services remain central to our strategy. In the first quarter, DSA revenue increased 12.0% compared with the prior-year period, and DSA net awards grew approximately 27% year-over-year. These results underscore the progress we are making toward building durable client relationships and a growing base of recurring business. We continue to advance our strategic initiatives and appreciate the continued support and trust of our employees, shareholders and partners."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NOTV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NOTV
Wall Street analysts forecast NOTV stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.271
Low
3.00
Averages
3.00
High
3.00
Current: 0.271
Low
3.00
Averages
3.00
High
3.00
About NOTV
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inotiv, Inc. Reports Q1 2026 Earnings with Strong DSA Growth
- DSA Revenue Growth: Inotiv's DSA revenue reached $48 million in Q1 2026, reflecting a 12% year-over-year increase, with discovery and translational sciences revenue up 26% and safety assessment revenue up 7%, showcasing strong performance despite challenges in the RMS segment.
- Significant New Awards: The company secured $53.6 million in new DSA awards during the quarter, a 27% increase from the previous year, indicating enhanced customer trust and scientific capabilities, which are expected to drive future revenue growth.
- Decline in RMS Revenue: RMS revenue fell to $72.9 million, a 5.4% decrease year-over-year, primarily due to lower NHP sales volumes; management anticipates margin improvements through site optimization and cost control measures in upcoming periods.
- Debt Restructuring Progress: Inotiv is collaborating with Perella Weinberg Partners to explore potential debt refinancing options; while no formal financial guidance is provided, management maintains a cautious outlook on future market clarity, emphasizing continued focus on DSA growth and innovation.
See More
Inotiv Reports Q1 Earnings Miss with Revenue Growth
- Earnings Performance: Inotiv's Q1 GAAP EPS of -$0.83 missed expectations by $0.19, indicating challenges in profitability, while revenue of $120.88 million grew 0.8% year-over-year, aligning with market expectations and reflecting the company's efforts to stabilize income.
- Adjusted EBITDA: The adjusted EBITDA for Q1 was $1.8 million, or 1.5% of total revenue, down from $2.6 million and 2.2% in the same quarter last year, highlighting pressures on cost control and profitability.
- Book-to-Bill Ratio: The book-to-bill ratio for DSA services in Q1 was 1.16, indicating stability in new order acquisition despite profitability challenges, suggesting potential for future revenue growth.
- Backlog Growth: As of December 31, 2025, DSA backlog reached $145.4 million, up from $138.2 million on September 30, 2025, and $130.4 million on December 31, 2024, signaling positive market demand for the company's services.
See More
Inotiv to Release Q1 2026 Financial Results on February 9
- Earnings Release Schedule: Inotiv will issue its financial results for the first quarter of fiscal 2026 on February 9, 2026, before the stock market opens, demonstrating the company's commitment to transparency and information disclosure.
- Conference Call Details: On the same day, Inotiv will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results, allowing investors to engage directly by dialing 1-800-445-7795 (Domestic) or 1-785-424-1699 (International), enhancing investor relations.
- Webcast Availability: The live conference call will be accessible via the Investors section of the company's website, ensuring that those unable to attend can access an online replay, reflecting the company's dedication to investor communication.
- Company Background Information: Inotiv is a leading contract research organization focused on nonclinical and analytical drug discovery and development services, committed to increasing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market, highlighting its significant role in the industry.
See More
Inotiv Partners with LifeNet Health to Enhance Drug Development Efficiency
- Strategic Collaboration: Inotiv announces a partnership with LifeNet Health to leverage the proprietary TruVivo® system, aiming to enhance drug development efficiency and accuracy by better aligning preclinical models with human biology.
- Technological Advantage: The TruVivo® system utilizes primary human hepatocytes, providing more physiologically relevant in vitro models, thereby addressing critical challenges in drug development and potentially accelerating the development of new therapies.
- Innovation Expansion: This collaboration extends beyond liver models to other human-relevant tissue models, fostering innovation for clients addressing a wide range of human diseases and enhancing market competitiveness.
- Shared Vision: The partnership reflects a mutual mission to accelerate scientific innovation and improve patient safety, expected to bring more human-relevant technologies to clinical research, driving the development of safer and more effective therapies.
See More
Inotiv Reports Q4 FY 2025 Revenue Growth of 5.9% to $138.1 Million
- Revenue Growth: Inotiv's Q4 FY 2025 revenue reached $138.1 million, a 5.9% increase driven primarily by a 15.7% rise in Discovery and Safety Assessment (DSA) revenue, indicating strong demand in the nonclinical drug development sector.
- Reduced Operating Loss: The operating loss for Q4 decreased by 48.5% to $6.8 million, reflecting effective cost control and revenue growth strategies, suggesting an improvement in the company's financial health.
- Annual Performance Improvement: Total revenue for FY 2025 was $513.0 million, up 4.5%, with Research Models and Services (RMS) revenue increasing by 4.7%, showcasing the company's stable growth potential in the market.
- Adjusted EBITDA Improvement: Q4 adjusted EBITDA was $11.8 million, or 8.5% of total revenue, significantly up from $5.4 million in the prior year, indicating ongoing enhancements in profitability and operational efficiency.
See More
Three Health Care Stocks That Could Revitalize Your Portfolio This November
Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.
Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.
Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.
See More
Inotiv, Inc. Reports Q1 2026 Earnings with Strong DSA Growth
- DSA Revenue Growth: Inotiv's DSA revenue reached $48 million in Q1 2026, reflecting a 12% year-over-year increase, with discovery and translational sciences revenue up 26% and safety assessment revenue up 7%, showcasing strong performance despite challenges in the RMS segment.
- Significant New Awards: The company secured $53.6 million in new DSA awards during the quarter, a 27% increase from the previous year, indicating enhanced customer trust and scientific capabilities, which are expected to drive future revenue growth.
- Decline in RMS Revenue: RMS revenue fell to $72.9 million, a 5.4% decrease year-over-year, primarily due to lower NHP sales volumes; management anticipates margin improvements through site optimization and cost control measures in upcoming periods.
- Debt Restructuring Progress: Inotiv is collaborating with Perella Weinberg Partners to explore potential debt refinancing options; while no formal financial guidance is provided, management maintains a cautious outlook on future market clarity, emphasizing continued focus on DSA growth and innovation.
See More
Inotiv Reports Q1 Earnings Miss with Revenue Growth
- Earnings Performance: Inotiv's Q1 GAAP EPS of -$0.83 missed expectations by $0.19, indicating challenges in profitability, while revenue of $120.88 million grew 0.8% year-over-year, aligning with market expectations and reflecting the company's efforts to stabilize income.
- Adjusted EBITDA: The adjusted EBITDA for Q1 was $1.8 million, or 1.5% of total revenue, down from $2.6 million and 2.2% in the same quarter last year, highlighting pressures on cost control and profitability.
- Book-to-Bill Ratio: The book-to-bill ratio for DSA services in Q1 was 1.16, indicating stability in new order acquisition despite profitability challenges, suggesting potential for future revenue growth.
- Backlog Growth: As of December 31, 2025, DSA backlog reached $145.4 million, up from $138.2 million on September 30, 2025, and $130.4 million on December 31, 2024, signaling positive market demand for the company's services.
See More
Inotiv to Release Q1 2026 Financial Results on February 9
- Earnings Release Schedule: Inotiv will issue its financial results for the first quarter of fiscal 2026 on February 9, 2026, before the stock market opens, demonstrating the company's commitment to transparency and information disclosure.
- Conference Call Details: On the same day, Inotiv will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results, allowing investors to engage directly by dialing 1-800-445-7795 (Domestic) or 1-785-424-1699 (International), enhancing investor relations.
- Webcast Availability: The live conference call will be accessible via the Investors section of the company's website, ensuring that those unable to attend can access an online replay, reflecting the company's dedication to investor communication.
- Company Background Information: Inotiv is a leading contract research organization focused on nonclinical and analytical drug discovery and development services, committed to increasing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market, highlighting its significant role in the industry.
See More
Inotiv Partners with LifeNet Health to Enhance Drug Development Efficiency
- Strategic Collaboration: Inotiv announces a partnership with LifeNet Health to leverage the proprietary TruVivo® system, aiming to enhance drug development efficiency and accuracy by better aligning preclinical models with human biology.
- Technological Advantage: The TruVivo® system utilizes primary human hepatocytes, providing more physiologically relevant in vitro models, thereby addressing critical challenges in drug development and potentially accelerating the development of new therapies.
- Innovation Expansion: This collaboration extends beyond liver models to other human-relevant tissue models, fostering innovation for clients addressing a wide range of human diseases and enhancing market competitiveness.
- Shared Vision: The partnership reflects a mutual mission to accelerate scientific innovation and improve patient safety, expected to bring more human-relevant technologies to clinical research, driving the development of safer and more effective therapies.
See More
Inotiv Reports Q4 FY 2025 Revenue Growth of 5.9% to $138.1 Million
- Revenue Growth: Inotiv's Q4 FY 2025 revenue reached $138.1 million, a 5.9% increase driven primarily by a 15.7% rise in Discovery and Safety Assessment (DSA) revenue, indicating strong demand in the nonclinical drug development sector.
- Reduced Operating Loss: The operating loss for Q4 decreased by 48.5% to $6.8 million, reflecting effective cost control and revenue growth strategies, suggesting an improvement in the company's financial health.
- Annual Performance Improvement: Total revenue for FY 2025 was $513.0 million, up 4.5%, with Research Models and Services (RMS) revenue increasing by 4.7%, showcasing the company's stable growth potential in the market.
- Adjusted EBITDA Improvement: Q4 adjusted EBITDA was $11.8 million, or 8.5% of total revenue, significantly up from $5.4 million in the prior year, indicating ongoing enhancements in profitability and operational efficiency.
See More
Three Health Care Stocks That Could Revitalize Your Portfolio This November
Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.
Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.
Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.
See More
